Ivabradine Grindeks

Ivabradine, the active ingredient in Ivabradine Grindeks, is a If channel inhibitor presented as an oral dosage form for oral use. It lowers heart rate and is indicated for chronic stable angina pectoris and heart failure with reduced ejection fraction in appropriate patients.

GNH USA supplies Ivabradine Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradine is an If channel inhibitor used in cardiovascular conditions that require heart‑rate reduction.

- Chronic stable angina pectoris: reduces the frequency of angina attacks by lowering heart rate. - Heart failure with reduced ejection fraction (in combination with beta‑blockers): improves symptoms and lowers the risk of hospitalization. - Patients intolerant to beta‑blockers: provides heart‑rate control without affecting myocardial contractility.

Ivabradine may cause a range of adverse reactions, most of which are mild to moderate.

Common Side Effects: - Bradycardia: heart rate falls below the desired range. - Visual disturbances (phosphenes): transient luminous phenomena. - Headache. - Dizziness. - Fatigue. - Blurred vision.

Serious or Rare Side Effects: - Symptomatic bradycardia requiring medical intervention. - Atrial fibrillation or other supraventricular arrhythmias. - Severe visual disturbances or persistent photopsia. - Hypotension leading to syncope. - Severe allergic reactions (e.g., rash, angioedema). - Conduction abnormalities such as heart block.

Before initiating therapy, clinicians should evaluate cardiovascular status and monitor heart rate regularly.

- Baseline heart rate assessment: ensure resting rate is above 70 bpm before starting. - Hepatic function: avoid or adjust dose in severe hepatic impairment. - Conduction disorders: contraindicated in sick sinus syndrome or advanced AV block. - Co‑administration with other bradycardic agents: use with caution when combined with beta‑blockers or digoxin. - CYP3A4 inhibitors: avoid strong inhibitors that may increase plasma levels. - Store at ambient temperature below 25 °C: keep in the original pack, protect from moisture.

Ivabradine may interact with several medicines that affect heart rate or its metabolism.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise ivabradine concentrations. - Concomitant use with other potent heart‑rate‑lowering drugs (e.g., beta‑blockers, digoxin) when excessive bradycardia is a risk. - Drugs causing severe sinus node dysfunction.

Moderate Interactions (Monitor Closely):\n- Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): may require dose adjustment. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Antihypertensive agents: monitor blood pressure for additive effects.